Latest News

UNICHEMLAB

Unichem Laboratories to hold 62nd Annual General Meeting on August 4, 2025

Source |11:12 20 Jun 25

agm-egm corporate actions regulatory filings

Unichem Laboratories Limited will hold its 62nd Annual General Meeting (AGM) on Monday, August 4, 2025, at 03:00 p.m. via video conference or other audio-visual means.
The beneficiary position for dispatch of annual reports to shareholders will be taken as on Friday, June 27, 2025.
The cut-off date for ascertaining shareholders eligible for voting on resolutions is Monday, July 28, 2025.

UNICHEMLAB

Unichem Labs Approves Audited FY25 Results, Reappoints & Appoints Auditors

Source |08:47 22 May 25

results corporate actions board changes regulatory filings

Unichem Laboratories Limited's Board of Directors approved the unaudited financial results (consolidated and standalone) for the quarter ended 31st March 2025, and the audited financial statements (consolidated and standalone) for the year ended 31st March 2025.
Re-appointed M/s. Kishore Bhatia & Associates as Cost Auditors for FY 2025-26.
Appointed M/s. Alwyn Jay & Co. as Secretarial Auditors for five years from FY 2025-26 to 2029-30, subject to members' approval.
Re-appointed M/s. Ram Agarwal & Associates as Internal Auditor for FY 2025-26.
Amended Code of Practices and Procedures for Fair Disclosure of UPSI as per SEBI regulations.
Consolidated revenue from operations for the quarter ended 31st March 2025 stood at ₹587.18 crore, and ₹2,110.97 crore for the year ended 31st March 2025.
Consolidated profit after tax for the quarter ended 31st March 2025 was ₹52.97 crore, and ₹137.52 crore for the year.
Standalone revenue from operations for the quarter ended 31st March 2025 was ₹461.24 crore, and ₹1,735.70 crore for the year.
Standalone profit after tax for the quarter ended 31st March 2025 was ₹51.22 crore, and ₹162.96 crore for the year.
During the year ended 31st March 2025, Unichem and its subsidiary Unichem Pharmaceutical (USA), Inc. entered into an agreement with Bayshore Pharmaceuticals LLC, USA for the purchase of rights, title and interest in product approvals and the USA generics formulations marketing/distribution business.
The company announced its intention to close the manufacturing facility of its wholly owned subsidiary Niche Generics Limited.
Subsequent to the year ended 31st March 2025, the Company has transferred its 100% stake in its wholly owned subsidiary Unichem Laboratories Limited, Ireland to Company's holding company , Ipca Laboratories Limited for a consideration of ₹4.00 crores.

UNICHEMLAB

Unichem Labs Completes Phase 1 Capacity Expansion at Pithampur Plant

Source |03:24 28 Apr 25

capex corporate actions press release

Unichem Laboratories Limited (UNICHEMLAB) announced the completion of Phase I capacity expansion at its API plant in Pithampur on 20 Mar 25. The expansion adds 210 KL to the existing capacity of 259.5 KL. The current capacity utilization is approximately 70%. The company invested approximately ₹200 crores for this expansion, which was financed through internal accruals and bank borrowings. The increased API production will primarily be used for captive purposes.

UNICHEMLAB

Unichem Labs Announces Trading Window Closure from 26 Mar 25

Source |03:24 28 Apr 25

regulatory filings corporate actions

Unichem Laboratories has announced the closure of its trading window for designated persons, directors, insiders, and their immediate relatives from 26 Mar 25. The trading window will reopen 48 hours after the declaration of the financial results for the quarter and year ending on 31 Mar 25. This closure is in accordance with the company's insider trading regulations.

UNICHEMLAB

Unichem Labs to Close Trading Window From 26 Mar 25

Source |03:24 28 Apr 25

corporate actions regulatory filings

Unichem Laboratories Limited (UNICHEMLAB) has announced the closure of its trading window for designated persons, directors, insiders, and their immediate relatives effective from 26 Mar 25. The trading window will reopen 48 hours after the declaration of the financial results for the quarter and year ending 31 Mar 25.